Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein promoting tumor aggressiveness by inhibiting protein phosphatase 2A (PP2A).
• Downregulation of CIP2A with small molecules reduces Akt phosphorylation and induces cancer cell death.
• Erlotinib is an EGFR inhibitor used in cancer therapy.

Purpose of the Study:

• To synthesize novel quinazoline and pyrimidine derivatives based on the erlotinib scaffold.
• To evaluate the antiproliferative activity of these derivatives against hepatocellular carcinoma.
• To investigate their mechanism of action involving CIP2A and Akt inhibition.

Main Methods:

• Synthesis of mono- and di-substituted quinazoline and pyrimidine derivatives.
• In vitro antiproliferative assays against hepatocellular carcinoma cell lines.
• Western blot analysis to assess CIP2A and phosphorylated Akt (p-Akt) expression.
• EGFR activity assays.

Main Results:

• Di-substituted derivatives exhibited greater antiproliferative potency than mono-substituted ones.
• Compound 1 induced cell death comparable to erlotinib without inhibiting EGFR.
• Compounds 19 and 22 demonstrated the most potent antiproliferative effects.
• Strong inhibition of CIP2A and p-Akt expression correlated with observed cell death.

Conclusions:

• Novel quinazoline and pyrimidine derivatives show significant potential as anticancer agents.
• These compounds effectively inhibit hepatocellular carcinoma cell proliferation via CIP2A and Akt pathways.
• Compounds 19 and 22 are promising candidates for further drug development against liver cancer.